NO311490B1 - Anvendelse av en pyridazinonforbindelse - Google Patents

Anvendelse av en pyridazinonforbindelse Download PDF

Info

Publication number: NO311490B1
Authority: NO; Norway
Prior art keywords: pyridazinone; txa2; chlorophenyl; compound; bromo
Prior art date: 1994-02-22

Application number

NO19963463A

Other languages

English (en)

Norwegian (no)

Other versions

NO963463L (no

Inventor

Ruriko Ikegawa

Teruaki Imada

Norifumi Nakamura

Keizo Tanikawa

Nobutomo Tsuruzoe

Original Assignee

Nissan Chemical Ind Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-22

Filing date

1996-08-20

Publication date

2001-12-03

1996-08-20 Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd

1996-08-20 Publication of NO963463L publication Critical patent/NO963463L/no

2001-12-03 Publication of NO311490B1 publication Critical patent/NO311490B1/no

Links

-1 pyridazinone compound Chemical class 0.000 title claims abstract description 32
150000003839 salts Chemical class 0.000 claims abstract description 14
239000003795 chemical substances by application Substances 0.000 claims abstract description 7
238000011321 prophylaxis Methods 0.000 claims abstract description 7
238000011282 treatment Methods 0.000 claims abstract description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
125000005843 halogen group Chemical group 0.000 claims description 11
125000002947 alkylene group Chemical group 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
208000033679 diabetic kidney disease Diseases 0.000 claims description 4
208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 3
WRTJKSNOFQWXAW-UHFFFAOYSA-N 5-bromo-3-(2,2-dimethyl-3-phenylpropoxy)-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=CC=CC=1CC(C)(C)COC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 WRTJKSNOFQWXAW-UHFFFAOYSA-N 0.000 claims description 2
PMLVYXZNSHKMEP-UHFFFAOYSA-N 5-chloro-3-(2,2-dimethyl-3-phenylpropoxy)-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=CC=CC=1CC(C)(C)COC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 PMLVYXZNSHKMEP-UHFFFAOYSA-N 0.000 claims description 2
QQPNYUDCLZIZNS-UHFFFAOYSA-N 5-chloro-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 QQPNYUDCLZIZNS-UHFFFAOYSA-N 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
OQXORNGBZMWMHO-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-4-[methyl(pyridin-3-yl)amino]-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1CC(C)(C)COC1=NNC(=O)C(Br)=C1N(C)C1=CC=CN=C1 OQXORNGBZMWMHO-UHFFFAOYSA-N 0.000 claims 1
COQQTKFVFMCTSU-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)-3-hydroxypropoxy]-4-[methyl(pyridin-3-yl)amino]-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1C(O)CCOC1=NNC(=O)C(Br)=C1N(C)C1=CC=CN=C1 COQQTKFVFMCTSU-UHFFFAOYSA-N 0.000 claims 1
YJMYSLFFZJUXOA-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 YJMYSLFFZJUXOA-UHFFFAOYSA-N 0.000 claims 1
102000003960 Ligases Human genes 0.000 abstract description 13
108090000364 Ligases Proteins 0.000 abstract description 13
201000010099 disease Diseases 0.000 abstract description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
230000001404 mediated effect Effects 0.000 abstract description 11
239000004480 active ingredient Substances 0.000 abstract description 6
239000003112 inhibitor Substances 0.000 abstract description 6
230000002401 inhibitory effect Effects 0.000 abstract description 6
230000000069 prophylactic effect Effects 0.000 abstract description 6
230000001225 therapeutic effect Effects 0.000 abstract description 6
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 abstract 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
229940126062 Compound A Drugs 0.000 description 6
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
238000000034 method Methods 0.000 description 6
210000001589 microsome Anatomy 0.000 description 6
239000000203 mixture Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000013049 sediment Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
239000000443 aerosol Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000002674 ointment Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
206010007556 Cardiac failure acute Diseases 0.000 description 2
206010008132 Cerebral thrombosis Diseases 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
201000001429 Intracranial Thrombosis Diseases 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
239000011575 calcium Substances 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000007788 liquid Substances 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
210000004623 platelet-rich plasma Anatomy 0.000 description 2
YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
HJYXVAZPXSDJAC-XFULWGLBSA-N 5-bromo-3-[(3r)-3-(4-chlorophenyl)-3-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one;hydrochloride Chemical compound Cl.C([C@@H](O)C=1C=CC(Cl)=CC=1)COC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 HJYXVAZPXSDJAC-XFULWGLBSA-N 0.000 description 1
HJYXVAZPXSDJAC-RSAXXLAASA-N 5-bromo-3-[(3s)-3-(4-chlorophenyl)-3-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one;hydrochloride Chemical compound Cl.C([C@H](O)C=1C=CC(Cl)=CC=1)COC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 HJYXVAZPXSDJAC-RSAXXLAASA-N 0.000 description 1
CSHCYQVKCLCXTK-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1CC(C)(C)COC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 CSHCYQVKCLCXTK-UHFFFAOYSA-N 0.000 description 1
HZVJNIUTIWSMAC-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)-3-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1C(O)CCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 HZVJNIUTIWSMAC-UHFFFAOYSA-N 0.000 description 1
QWGUGDYWUADMGB-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 QWGUGDYWUADMGB-UHFFFAOYSA-N 0.000 description 1
AVGCJKOSOVAHOX-UHFFFAOYSA-N 5-chloro-3-(3-phenylpropoxy)-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=CC=CC=1CCCOC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 AVGCJKOSOVAHOX-UHFFFAOYSA-N 0.000 description 1
ADAGMNCCEJMUMC-UHFFFAOYSA-N 5-chloro-3-[3-(4-chlorophenyl)-2-hydroxypropoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one Chemical compound C=1C=C(Cl)C=CC=1CC(O)COC1=NNC(=O)C(Cl)=C1NCC1=CC=CN=C1 ADAGMNCCEJMUMC-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000022309 Alcoholic Liver disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000033386 Buerger disease Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000011200 Kawasaki disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
108010069102 Thromboxane-A synthase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical group OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940124572 antihypotensive agent Drugs 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000003177 cardiotonic effect Effects 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000007789 gas Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229940051841 polyoxyethylene ether Drugs 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
229940082004 sodium laurate Drugs 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical class C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Confectionery (AREA)
Medicines Containing Plant Substances (AREA)
Pyridine Compounds (AREA)

NO19963463A 1994-02-22 1996-08-20 Anvendelse av en pyridazinonforbindelse NO311490B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2455694		1994-02-22
PCT/JP1995/000244 WO1995022329A1 (en)	1994-02-22	1995-02-20	Agent for prophylaxis and treatment of thromboxane a2-mediated diseases

Publications (2)

Publication Number	Publication Date
NO963463L NO963463L (no)	1996-08-20
NO311490B1 true NO311490B1 (no)	2001-12-03

Family

ID=12141437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19963463A NO311490B1 (no)	1994-02-22	1996-08-20	Anvendelse av en pyridazinonforbindelse

Country Status (16)

Country	Link
US (1)	US5798357A (de)
EP (1)	EP0744950B1 (de)
JP (1)	JP3858279B2 (de)
KR (1)	KR100345187B1 (de)
CN (1)	CN1084620C (de)
AT (1)	ATE273708T1 (de)
AU (1)	AU1718395A (de)
CA (1)	CA2183234C (de)
DE (1)	DE69533392T2 (de)
DK (1)	DK0744950T3 (de)
ES (1)	ES2222464T3 (de)
FI (1)	FI116882B (de)
IL (1)	IL112695A (de)
NO (1)	NO311490B1 (de)
WO (1)	WO1995022329A1 (de)
ZA (1)	ZA951470B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW482675B (en) *	1997-01-31	2002-04-11	Green Cross Corp	Compositions for oral administration containing pyridazinone compounds technical field of the invention
WO1999011268A1 (en) *	1997-08-28	1999-03-11	Yoshitomi Pharmaceutical Industries, Ltd.	Neovascularization promoters and neovascularization potentiators
US6143113A (en)	1998-03-02	2000-11-07	Le Groupe Recherche I.D. Inc.	Repulpable corrugated boxboard
CA2342198C (en)	1998-09-01	2007-08-28	Welfide Corporation	Therapeutic agent for spinal canal stenosis
CN1163230C (zh) *	1998-12-07	2004-08-25	日产化学工业株式会社	勃起功能障碍治疗剂
KR20060125816A (ko) *	2003-12-26	2006-12-06	닛산 가가쿠 고교 가부시키 가이샤	호중구증다 억제제
CA2714160A1 (en) *	2008-01-29	2009-08-06	Indigo Pharmaceuticals	A method of administering a pde3 inhibitor via titration for the treatment of peripheral arterial disease
CN113546049B (zh) *	2021-04-30	2023-03-17	贵州汉方药业有限公司	一种柔性丸剂药物黏合剂及使用该黏合剂制成的柔性丸剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4599336A (en) *	1983-08-08	1986-07-08	Hoffmann-La Roche Inc.	Derivatives of (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenamide
EP0142057A3 (de) *	1983-11-04	1988-03-30	F. Hoffmann-La Roche Ag	Thiazolochinazolin-Derivate, ihre Herstellung und sie enthaltende pharmazeutische Zubereitungen
HU198696B (en) *	1987-01-20	1989-11-28	Nissan Chemical Ind Ltd	Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components
JPH02256668A (ja) *	1988-12-20	1990-10-17	Nissan Chem Ind Ltd	ピリダジノン誘導体
DK0482208T3 (da) *	1990-04-25	2000-09-18	Nissan Chemical Ind Ltd	Pyridazinonderivat

1995
- 1995-02-19 IL IL11269595A patent/IL112695A/xx not_active IP Right Cessation
- 1995-02-20 EP EP95909122A patent/EP0744950B1/de not_active Expired - Lifetime
- 1995-02-20 KR KR1019960704529A patent/KR100345187B1/ko not_active Expired - Lifetime
- 1995-02-20 CN CN95191744A patent/CN1084620C/zh not_active Expired - Lifetime
- 1995-02-20 CA CA002183234A patent/CA2183234C/en not_active Expired - Lifetime
- 1995-02-20 ES ES95909122T patent/ES2222464T3/es not_active Expired - Lifetime
- 1995-02-20 AT AT95909122T patent/ATE273708T1/de active
- 1995-02-20 DE DE69533392T patent/DE69533392T2/de not_active Expired - Lifetime
- 1995-02-20 WO PCT/JP1995/000244 patent/WO1995022329A1/en not_active Ceased
- 1995-02-20 US US08/687,604 patent/US5798357A/en not_active Expired - Lifetime
- 1995-02-20 AU AU17183/95A patent/AU1718395A/en not_active Abandoned
- 1995-02-20 DK DK95909122T patent/DK0744950T3/da active
- 1995-02-21 JP JP03230095A patent/JP3858279B2/ja not_active Expired - Fee Related
- 1995-02-22 ZA ZA951470A patent/ZA951470B/xx unknown
1996
- 1996-08-20 NO NO19963463A patent/NO311490B1/no not_active IP Right Cessation
- 1996-08-21 FI FI963264A patent/FI116882B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69533392D1 (de)	2004-09-23
US5798357A (en)	1998-08-25
CN1141590A (zh)	1997-01-29
CN1084620C (zh)	2002-05-15
DK0744950T3 (da)	2004-10-25
IL112695A (en)	1999-04-11
ES2222464T3 (es)	2005-02-01
ATE273708T1 (de)	2004-09-15
KR100345187B1 (ko)	2002-12-05
NO963463L (no)	1996-08-20
EP0744950B1 (de)	2004-08-18
FI963264A0 (fi)	1996-08-21
FI116882B (fi)	2006-03-31
EP0744950A1 (de)	1996-12-04
JPH07285869A (ja)	1995-10-31
FI963264A7 (fi)	1996-08-21
WO1995022329A1 (en)	1995-08-24
ZA951470B (en)	1995-12-07
IL112695A0 (en)	1995-05-26
CA2183234A1 (en)	1995-08-24
AU1718395A (en)	1995-09-04
DE69533392T2 (de)	2005-09-01
CA2183234C (en)	2004-05-04
JP3858279B2 (ja)	2006-12-13
KR970701048A (ko)	1997-03-17

Legal Events

Date	Code	Title	Description
2015-03-02	MK1K	Patent expired

Publication	Publication Date	Title
US4661499A (en)	1987-04-28	2-[(substituted)-phenoxymethyl]quinolines
JP5872552B2 (ja)	2016-03-01	化学化合物
EA011895B1 (ru)	2009-06-30	Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
JP2013532185A (ja)	2013-08-15	化合物
TW200831089A (en)	2008-08-01	Substituted bicyclocarboxyamide compounds
TW200822924A (en)	2008-06-01	Pyrazoline compounds
JP2009514848A (ja)	2009-04-09	医薬組成物
NO311490B1 (no)	2001-12-03	Anvendelse av en pyridazinonforbindelse
EA007952B1 (ru)	2007-02-27	Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
JP6275517B2 (ja)	2018-02-07	Ｉｌ−２産生抑制
TW201031659A (en)	2010-09-01	Novel compound having 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3H)-on structure and medicine containg same
EP3091001B1 (de)	2017-11-22	Diphenylmethyl-piperazin-derivat und pharmazeutische zusammensetzung damit
CN100502861C (zh)	2009-06-24	抑制钠/钙交换系统的药剂
EP1714654A1 (de)	2006-10-25	Arzneimittel zur hemmung von vaskulärer intimahyperplasie
CZ20012020A3 (cs)	2001-10-17	Činidlo pro léčbu erektilní dysfunkce
WO2013093688A1 (en)	2013-06-27	Sulfonamide derivatives and use thereof as vgsc inhibitors
CN101102775A (zh)	2008-01-09	采用pdev抑制剂治疗充血性心衰的方法
CN101304744A (zh)	2008-11-12	包含阿伐他汀衍生物的药物组合物
EP1171133B1 (de)	2006-06-21	R-hydroxynefazodon
CN121889392A (zh)	2026-04-17	一种FabI酶抑制剂及其应用
WO1997046515A1 (en)	1997-12-11	Substituted benzenes having nos inhibitory effects
KR20100019542A (ko)	2010-02-18	호중구증다 억제제
CA2369225A1 (en)	2000-10-19	S-hydroxynefazodone
HK40004003A (en)	2020-04-17	Griseofulvin compound
CA2714160A1 (en)	2009-08-06	A method of administering a pde3 inhibitor via titration for the treatment of peripheral arterial disease